Coexistence of SARS-CoV-2 and Tuberculosis
Keywords:
TUBERCULOSIS, ANTIBIOTICS, SARS-COV-2.Abstract
Introduction: the coexistence of tuberculosis (TB) and COVID-19 presents a significant medical challenge. Both diseases, which have different etiologies, Mycobacterium tuberculosis and SARS-CoV-2 respectively, affect the lungs and share severe respiratory manifestations.
Objective: to describe a case with coexistence of tuberculosis (TB) and SARS-CoV-2 disease (COVID-19).
Case presentation: a 21-year-old male patient is presented who presented an onset clinical picture compatible with pneumonia, etiology of COVID-19, due to the complications that the patient presented such as pleural effusion and bronchiectasis, the investigation was expanded with a subsequent diagnosis for pulmonary tuberculosis. The serological results and the cytochemistry of the pleural fluid support the complexity of the situation. This case reinforces the importance of understanding the interaction between both diseases for effective treatment and highlights the need for a comprehensive approach in health care.
Conclusions: this clinical case underlines the need to understand the interaction between tuberculosis and COVID-19 to provide effective treatment and improve clinical outcomes.
Downloads
References
1. Visca D, Ong CWM, Tiberi S, Centis R, D’Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology [Internet]. 2021 [citado 20/01/2024]; 27(2): 151–165. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7825946/
2. Benites Suárez CM, Lopez Silva CM. COVID-19 y tuberculosis: El encuentro entre nuevas amenazas y viejas enfermedades. Rev. Fac. Med. Hum. [Internet]. 2021 Ene [citado 09/12/2024]; 21(1): 251-252. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2308-05312021000100251&lng=es.
3. OPS. Ecuador refuerza la lucha contra la tuberculosis impulsando el diagnóstico y tratamiento [Online]. OPS; 2023 [cited 18/10/023]. Available from: https://www.paho.org/es/noticias/18-9-2023-ecuador-refuerza-lucha-contra-tuberculosis-impulsando-diagnostico-tratamiento
4. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med [Internet]. 2021 Mar 1 [citado 09/12/2024]; 29(1): 20-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33664170/
5. Purohit D, Ahirwar AK, Sakarde A, Asia P, Gopal N. COVID-19 and lung pathologies. Horm Mol Biol Clin Investig [Internet]. 2021 Aug 2 [citado 09/12/2024 ]; 42(4): 435-443. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34333882/
6. Vázquez JB, Menchén DA, Lloréns MMM, Moreno JS. Manifestaciones sistémicas y extrapulmonares en la COVID-19 [Systemic and extrapulmonary manifestations of COVID-19]. Medicine (Madr) [Intenet]. 2022 May [citado 09/12/2024 ]; 13(55): 3235-3245. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9097973/
7. Parolina L, Pshenichnaya N, Vasilyeva I, Lizinfed I, Urushadze N, Guseva V, et al. Clinical characteristics of COVID-19 in patients with tuberculosis and factors associated with the disease severity. Int J Infect Dis [Internet]. 2022 Nov [citado 09/12/2024 ]; 124 (Suppl 1): S82-S89. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35483555/
8. Therese LK, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infectious Diseases [Internet]. 2020 Agosto [citado 09/12/2024 ]; 52(12): 902-907. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32808838/
9. European Respiratory Society. Tuberculosis and COVID-19 co-infection: description of the global cohort. EUROPEAN RESPIRATORY journal [Internet]. 2022 Marzo [citado 09/12/2024 ]; 59(3): 2102538. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34764184/
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
